pituitary disorders

in review 6 min read Updated 2026-11-19
pituitary disorders

Evaluate every sellar mass across three axes: mass effect (bitemporal hemianopia, CN III/IV/VI palsy), hormone hypersecretion (prolactin, IGF-1, cortisol), and hypopituitarism (ACTH, TSH, LH/FSH, GH, AVP). In pituitary apoplexy, give IV hydrocortisone 100 mg immediately; urgent surgical decompression is reserved for worsening visual fields/acuity or reduced consciousness, while isolated ocular palsy can often be managed conservatively. Always replace glucocorticoids before levothyroxine, and monitor central hypothyroidism with free T4 (never TSH).

do not miss
  • Pituitary apoplexy: sudden severe thunderclap headache + visual loss, ophthalmoplegia, or hypotension → give IV hydrocortisone 100 mg immediately before MRI/surgery.
  • Starting levothyroxine before excluding central adrenal insufficiency: accelerates cortisol metabolism and can trigger adrenal crisis.
  • Unmasking AVP deficiency (central diabetes insipidus): starting glucocorticoids in cortisol-deficient panhypopituitarism restores free-water excretion and can unmask severe polyuria and hypernatraemia.

evaluating a pituitary mass or incidentaloma (ES 2011)

  • Dedicated pituitary MRI (thin-slice with gadolinium) if discovered on CT
  • Formal visual field (perimetry) testing: mandatory whenever the lesion abuts or compresses the optic nerves or chiasm
  • Biochemical screening for all incidentalomas (even if asymptomatic):
    • Hypersecretion: serum prolactin (dilute 1:100 if macroadenoma with paradoxically normal/mildly elevated PRL to exclude hook effect — see hyperprolactinaemia), age-adjusted IGF-1, and screen for cushing syndrome if clinical clues exist
    • Hypopituitarism (especially macroadenomas ≥10 mm and large microadenomas): 08:00 cortisol (+ ACTH), TSH + free T4, LH/FSH + morning total testosterone (men) or oestradiol (premenopausal oligo/amenorrhoeic women), and IGF-1
  • Typical order of anterior pituitary hormone loss with progressive compression: GH → LH/FSH → TSH → ACTH → PRL (remember: ICI hypophysitis and lymphocytic hypophysitis frequently violate this order and present early with isolated ACTH or TSH deficiency)
  • Indications for transsphenoidal surgery (ES 2011, strong):
    • Visual field deficit or other visual/neurologic compromise (e.g., ophthalmoplegia) from tumour compression
    • Lesion abutting or compressing the optic nerves or chiasm
    • Pituitary apoplexy with visual disturbance
    • Functioning tumour other than a prolactinoma (prolactinomas receive cabergoline first, though Knosp 0–1 micro/well-encased macroprolactinomas may discuss upfront surgery)
  • Surveillance if non-surgical:
    • Macroincidentaloma (≥10 mm): repeat MRI at 6 months, then yearly for 3 years, then progressively less frequently; reassess pituitary function at 6 months and yearly; repeat visual fields if growing or abutting chiasm
    • Microincidentaloma (<10 mm): repeat MRI at 1 year, then every 1–2 years for 3 years, then progressively less frequently; no repeat hypopituitarism testing needed if clinically and radiologically stable

hypopituitarism replacement (ES 2016)

axisdiagnosisreplacement & monitoring
ACTH (central AI)08:00 cortisol <80 nmol/L confirms; >400–500 nmol/L excludes; intermediate → 250 µg cosyntropin stim (peak <500 nmol/L, assay-dependent; unreliable <4–6 wk post-surgery/apoplexy)hydrocortisone 15–20 mg/day in 2–3 divided doses (first axis replaced); no fludrocortisone; monitor clinically + sick-day rules + emergency IM hydrocortisone
TSH (central hypothyroidism)low free T4 with low, normal, or mildly elevated TSH (never screen with TSH alone)levothyroxine ~1.6 µg/kg/day (lower start in elderly/CAD) only after AI excluded/treated; titrate free T4 into the mid to upper half of the reference range (ignore TSH; avoid over-replacement — vertebral fracture risk)
LH/FSH (central hypogonadism)low morning testosterone (men) or low oestradiol + oligo/amenorrhoea (premenopausal women) with low/normal LH & FSHmen: testosterone (if fertility not currently desired); premenopausal women: oestrogen (+ progestin if intact uterus) until natural menopause (~50 y); gonadotropins if fertility desired
GHlow IGF-1 in ≥3 other pituitary hormone deficiencies suffices; otherwise dynamic testing (e.g., glucagon or insulin tolerance test)recombinant GH in selected symptomatic adults; contraindicated in active malignancy; titrate to age-adjusted IGF-1; may unmask central AI or central hypothyroidism (recheck cortisol and free T4)
AVP (central DI)hypotonic polyuria + hypernatraemia; note triphasic post-op response (DI → SIADH at ~5–7 d → permanent/transient DI)desmopressin (DDAVP); titrate to relieve polyuria while avoiding hyponatraemia (see hypernatraemia and diabetes insipidus)
  • Oral oestrogen interactions: oral oestrogen increases TBG and CBG (raising levothyroxine requirements and elevating total serum cortisol) and blunts hepatic IGF-1 response to GH (transdermal oestrogen avoids these effects)

pituitary apoplexy (UK 2011; 2026 review)

Sudden haemorrhage or infarction within a pituitary tumour (often previously undiagnosed; precipitants include surgery, anticoagulation, pregnancy/Sheehan-like states, hypertension, dopamine agonists, dynamic pituitary testing). Presents with acute severe retro-orbital/frontal headache (>90%), visual acuity/field loss, diplopia (CN III, IV, VI), nausea/vomiting, and adrenal crisis; AVP deficiency is uncommon at presentation (<5%).

suspected pituitary apoplexy

Acute severe headache with visual loss, ophthalmoplegia, or hypotension — give IV steroids immediately, then decide surgery vs conservative care.

first
  • draw cortisol, free T4, TSH, PRL, IGF-1, LH/FSH, and electrolytes; give IV hydrocortisone 100–200 mg bolus immediately
  • continue hydrocortisone 2–4 mg/h IV infusion or 50–100 mg IM q6h (intermittent IV less favoured); stabilise hyponatraemia
then / if needed
  • obtain dedicated pituitary MRI once stable (within 24 h) and formal neuro-ophthalmic exam (acuity, fields, CN III/IV/VI)
  • transsphenoidal decompression (UK 2011: ideally ≤7 d; timing debated) for severe/worsening visual loss or low GCS
  • conservative care (steroids + daily eye exams) is safe if stable with isolated ocular palsy or mild non-progressive deficits
avoid
  • oral steroids initially (vomiting impairs absorption) or relying on CT alone or PAS alone to decide surgery
  • Follow-up: formal pituitary reassessment at 4–8 weeks (including morning cortisol/dynamic testing off steroids if clinically appropriate, free T4/TSH, gonadal/GH axes); repeat pituitary MRI at 3–6 months, then annually for 5 years and biennially thereafter

acromegaly (ES 2014)

  • Clinical suspicion: acral enlargement (increasing ring/shoe size), coarse facial features, prognathism, macroglossia, carpal tunnel syndrome, OSA, diaphoresis, skin tags, hypertrophic cardiomyopathy, diabetes, arthropathy, colonic polyps
  • Diagnosis:
    1. Serum IGF-1 (age- and sex-adjusted) is the single best screening test (never use random GH to diagnose acromegaly due to pulsatility)
    2. Confirmatory test: 75-g oral glucose tolerance test (OGTT) with GH measurements — failure of GH to suppress to <1 µg/L (note: hypersensitive assays often use <0.4 µg/L) confirms acromegaly
    3. Pituitary MRI after biochemical confirmation (>75% are macroadenomas); assess visual fields if abutting chiasm and screen for hypopituitarism + co-secreted prolactin
  • Treatment and targets:
    • First-line: transsphenoidal surgery by an experienced pituitary surgeon (curative in >80% of microadenomas, ~50% of macroadenomas)
    • Biochemical targets: age-normalised IGF-1 and random GH <1.0 µg/L (recheck at ≥12 weeks post-op)
    • Medical therapy (persistent post-op disease or non-surgical candidates):
      • First-generation somatostatin receptor ligands (SRLs): octreotide LAR or lanreotide first-line (GI upset, gallstones, mild dysglycaemia)
      • Pegvisomant (GH receptor antagonist): highly effective for SRL-resistant disease; monitor IGF-1 only (GH levels rise and are uninterpretable); monitor LFTs and MRI for tumour growth
      • Pasireotide (second-generation SRL): higher efficacy in refractory cases, but high rate of hyperglycaemia
      • Cabergoline: adjunct or option for modest IGF-1 elevation and mild symptoms
    • Radiotherapy (stereotactic radiosurgery): third-line for residual/progressive tumour after surgery and medical therapy (causes delayed hypopituitarism over years)
    • Comorbidity screening: colonoscopy at diagnosis (repeat per polyp/IGF-1 status), sleep apnoea assessment, echocardiography/BP/glycaemic control

Prepared 2026-11-19. Not yet verified — check every number against the sources.

Key references

+1 more source

Suggest a correction pituitary disorders